TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16674968

Group type: EXPERIMENTAL
Intervention: Prereading children articulating shared heads, codas, and onsets
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Precocious readers articulating shared rimes
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Detection task for rimes and heads
Number of subjects: 91
Study: 14960254

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 209

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 209
Study: 11412554

Group type: EXPERIMENTAL
Intervention: Systematic minimal intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: One-off medical counselling
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) with nicotine patches (11% nicotine)
Number of subjects: 304
Study: 9562759

Group type: EXPERIMENTAL
Intervention: Local injection of long-acting corticosteroid
Number of subjects: 55
Study: 7913738

Group type: EXPERIMENTAL
Intervention: Talipexole
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2603190

Group type: EXPERIMENTAL
Intervention: Hand washing intervention with 2 bars of plain soap
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group following customary practice
Number of subjects: 494
Study: 4599859

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 62
Study: 30152737

Group type: EXPERIMENTAL
Intervention: Listening to an RIA recording several times before and during the session
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: In-session RIA intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Listening to relaxing music (control condition)
Number of subjects: 60
Study: 27062956

Group type: EXPERIMENTAL
Intervention: Honey consumption (2.5 g/kg body weight per dose, twice weekly for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Honey withdrawal (after intervention)
Number of subjects: 40
Study: 25898184

Group type: EXPERIMENTAL
Intervention: Teaching Kids to Cope with Anger (TKC‐A) program
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 179
Study: 23713298

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 50
Study: 20517177

Group type: EXPERIMENTAL
Intervention: Evl trough levels >= 3 ng/mL
Number of subjects: 92

Group type: COMPARATOR
Intervention: Evl trough levels < 3 ng/mL
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-dose Tac
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard-dose Tac
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Evl and Tac levels
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 92
Study: 19057271

Group type: EXPERIMENTAL
Intervention: erlotinib (150 mg PO per day)
Number of subjects: 311
Study: 17144179

Group type: EXPERIMENTAL
Intervention: Use of racial categories in medicine as an interim step
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up inquiry into factors underlying race-correlated clinical differences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revisiting market and regulatory incentives regarding race in medicine
Number of subjects: 0
Study: 14584383

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg, 3 days)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) (25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine, single dose)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg, 3 days)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Chloroquine (in children aged < 5 years)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Amodiaquine (in children aged < 5 years)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: No treatment failures (in adults)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Children aged 5-15 years
Number of subjects: 342
Study: 10928213

Group type: EXPERIMENTAL
Intervention: Combination of cognitive and action strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Action oriented strategies
Number of subjects: 0
Study: 8735151

Group type: EXPERIMENTAL
Intervention: Deviant tones with a 4.5 s interstimulus interval (ISI)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Deviant tones with a 0.5 s ISI
Number of subjects: 26
Study: 1356480

Group type: COMPARATOR
Intervention: R1 resection
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: R2 resection
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: R2 resection by Japanese instructor
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: R2 resection by Dutch supervisors
Number of subjects: 192
Study: 3863847

Group type: EXPERIMENTAL
Intervention: Super Floss
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waxed dental floss
Number of subjects: 34
Study: 30030005

Group type: EXPERIMENTAL
Intervention: Proximal interphalangeal joint‐blocking orthosis (PIPJ‐BO)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Metacarpophalangeal joint‐blocking orthosis (MCPJ‐BO)
Number of subjects: 35
Study: 29384848

Group type: EXPERIMENTAL
Intervention: Short‐cycle therapy (SCT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Continuous therapy
Number of subjects: 199
Study: 27499054

Group type: EXPERIMENTAL
Intervention: Peer counselling about LARC with routine contraceptive counselling
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine counselling alone
Number of subjects: 110
Study: 25456803

Group type: EXPERIMENTAL
Intervention: School garden intervention
Number of subjects: 227

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 227
Study: 22516666

Group type: EXPERIMENTAL
Intervention: Venlafaxine (150 mg daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pregabalin (200 mg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20801178

Group type: EXPERIMENTAL
Intervention: Soft luncheon meat
Number of subjects: 106

Group type: COMPARATOR
Intervention: Hard luncheon meat
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ad libitum intake
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Texture differences
Number of subjects: 106
Study: 19102944

Group type: EXPERIMENTAL
Intervention: rhTPO (15,000 U/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: rhIL-11 (3 mg/d)
Number of subjects: 72
Study: 15718048

Group type: EXPERIMENTAL
Intervention: 6-[18F]fluoro-L-dopa (Fdopa) PET scan
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neuropsychological test battery (VIG and Stroop tests)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 12841801

Group type: EXPERIMENTAL
Intervention: Pharmacist-administered detailed questionnaires, tailored education regarding medication use, help with appointment referrals, and creation of a summary of adherence barriers and medication discrepancies.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10663363

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/day
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1226
Study: 8863082

Group type: EXPERIMENTAL
Intervention: Violence Prevention Curriculum for Adolescents
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conflict Resolution: A Curriculum for Youth Providers
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Both curricula
Number of subjects: 225
Study: 1446212

Group type: EXPERIMENTAL
Intervention: Words presented to the right visual field (RVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Words presented to the left visual field (LVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pairs of nouns with close semantic associations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pairs of nouns with distant semantic associations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomly matched pairs of nouns
Number of subjects: 0
Study: 3081082

Group type: EXPERIMENTAL
Intervention: Computed tomography of the thorax
Number of subjects: 300
Study: 30332407

Group type: EXPERIMENTAL
Intervention: Virtual Reality perspective-taking task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional perspective-taking task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desktop computer perspective-taking task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (fact-driven information about the homeless)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional and less immersive conditions
Number of subjects: 0
Study: 27150916

Group type: EXPERIMENTAL
Intervention: 750 mg of Tranexamic Acid (TXA) daily until complete radiological resolution of the CSDH or for a maximum of 20 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 750 mg of Tranexamic Acid (TXA) daily
Number of subjects: 130
Study: 24329965

Group type: EXPERIMENTAL
Intervention: Preoperative transfusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: No preoperative transfusion
Number of subjects: 70
Study: 22832811

Group type: EXPERIMENTAL
Intervention: Standardized postoperative laxative protocol (n=19) including sterculia and frangula bark (Normacol Plus) and liquid paraffin (Agarol); second-line treatment with Movicol.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ad hoc laxative intervention(s) as preferred by the surgical team (n=26).
Number of subjects: 45
Study: 21045097

Group type: EXPERIMENTAL
Intervention: Fall Prevention Tool Kit (FPTK)
Number of subjects: 10264

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10264
Study: 15679463

Group type: EXPERIMENTAL
Intervention: Quadrant test (physical examination procedure)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Lateral flexion (physical examination procedure)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Lower-extremity weakness (physical examination procedure)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Lumbar extension (physical examination procedure)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Not applicable (no lumbar PE procedure)
Number of subjects: 74
Study: 14682645

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 81

Group type: COMPARATOR
Intervention: Zinc oxide-eugenol (ZOE) cement
Number of subjects: 81

Group type: COMPARATOR
Intervention: Composite
Number of subjects: 81
Study: 10754353

Group type: EXPERIMENTAL
Intervention: Automatic pacemaker function (Capturecontrol)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Manual pacing threshold measurement
Number of subjects: 14
Study: 7611757

Group type: EXPERIMENTAL
Intervention: 5'-DFUR (oral administration at a mean dose of 10.0 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no 5'-DFUR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (5'-DFUR and Control)
Number of subjects: 0
Study: 2122498

Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning protocol specific to the elderly implemented by a gerontological nurse specialist
Number of subjects: 280

Group type: COMPARATOR
Intervention: Routine discharge planning
Number of subjects: 280
Study: 598366

Group type: EXPERIMENTAL
Intervention: Pedalling rate varied from 40 to 100 rpm at constant work load.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work load varied from 2.5 to 10 mkp/s (patients) and 5 to 20 mkp/s (normals).
Number of subjects: 0
Study: 30811141

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 909

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 909
Study: 28604179

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26222347

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAPB) with 15 mL of 0.5% ropivacaine per side
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rectus sheath block (RSB) with 15 mL of 0.5% ropivacaine per side
Number of subjects: 22
Study: 24239202

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1002
Study: 21150627

Group type: EXPERIMENTAL
Intervention: Ultrasound-aided ipsilateral-dominant block using 6 ml of lidocaine 1.5%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia using ropivacaine 0.2%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midline approach for epidural puncture
Number of subjects: 24
Study: 18639297

Group type: EXPERIMENTAL
Intervention: Tolterodine extended release plus tamsulosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0
Study: 16828595

Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg once daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Azimilide
Number of subjects: 220
Study: 12616662

Group type: EXPERIMENTAL
Intervention: Oral thrombin inhibitor LB-30057 (CI-1028)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct addition of LB-30057 to blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coagulation tests
Number of subjects: 0
Study: 10837293

Group type: EXPERIMENTAL
Intervention: High-sucrose meal with 200 mg [13C]fructose
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-sucrose meal with 200 mg [13C]glucose
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-starch meal with 200 mg [13C]glucose
Number of subjects: 7
Study: 9265198

Group type: EXPERIMENTAL
Intervention: Feldenkrais Method 'Awareness through Movement'
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no Feldenkrais course)
Number of subjects: 15
Study: 8255966

Group type: EXPERIMENTAL
Intervention: Self-testing for post-prandial glycosuria
Number of subjects: 13495

Group type: COMPARATOR
Intervention: Fasting plasma glucose of 6 mmol/l
Number of subjects: 13495

Group type: COMPARATOR
Intervention: Normal population control group (442 subjects from Ely)
Number of subjects: 13495
Study: 2880459

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30087174

Group type: EXPERIMENTAL
Intervention: Conventional PD solution
Number of subjects: 165

Group type: COMPARATOR
Intervention: Biocompatible PD solution
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Peritoneal glucose exposure
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Peritoneal glucose degradation product content
Number of subjects: 165
Study: 26813527

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (800 kcal) for 8 weeks
Number of subjects: 667
Study: 25495811

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22921262

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 30
Study: 20529406

Group type: EXPERIMENTAL
Intervention: Overall dietary diversity
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Within-food group dietary diversity (especially in bread and cereals, vegetables, dairy products, and spreadable fats)
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Diversity within the dairy and spreadable fat group
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Diversity within the meat and energy-dense, nutrient-poor food groups
Number of subjects: 3245
Study: 18177776

Group type: COMPARATOR
Intervention: Haloperidol (n=28)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Risperidone (n=29)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 86
Study: 15649235

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (PTCA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 72
Study: 11900290

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ibutilide
Number of subjects: 33

Group type: COMPARATOR
Intervention: saline
Number of subjects: 33
Study: 10333900

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 19
Study: 8837958

Group type: EXPERIMENTAL
Intervention: L-NAME (NO synthase inhibitor) at doses of 40 micrograms/kg injected plus 50 micrograms/kg infused i.v.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 7
Study: 1978880

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6987113

Group type: EXPERIMENTAL
Intervention: Viloxazine (100 to 200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30904596

Group type: EXPERIMENTAL
Intervention: Standard Tobacco Quitline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialized Tobacco Quitline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard Tobacco Quitline with Basic Needs Navigation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialized Tobacco Quitline with Basic Needs Navigation
Number of subjects: 0
Study: 30072407

Group type: EXPERIMENTAL
Intervention: Dietary intervention aiming to improve the quality of dietary fat and promote intake of vegetables, fruits, and whole-grain products, with biannual counseling based on Nordic Nutrition Recommendations.
Number of subjects: 941
Study: 26840437

Group type: EXPERIMENTAL
Intervention: Ad libitum (AL) hydration protocol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Individualized rehydration (IR) hydration protocol
Number of subjects: 13
Study: 25173064

Group type: EXPERIMENTAL
Intervention: Four new healthy snack products (fruit, vegetables, bread, dip, topping)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Health consciousness
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Snack neophobia
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Peer influence
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Social activities
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Word-of-mouth
Number of subjects: 600
Study: 22879630

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin followed by metformin 1500 mg daily
Number of subjects: 40
Study: 21159599

Group type: EXPERIMENTAL
Intervention: Internet Doctor website
Number of subjects: 714
Study: 17397460

Group type: EXPERIMENTAL
Intervention: Ibuprofen alone (5 mg kg(‐1))
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Paracetamol and ibuprofen combination (15/5 mg kg(‐1))
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: High-dose paracetamol (20 mg kg(‐1))
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual-dose paracetamol (15 mg kg(‐1))
Number of subjects: 201
Study: 15721993

Group type: EXPERIMENTAL
Intervention: Estrogen-gestagen combination drug (17beta-estradiol+norethisterone acetate) with antipsychotic drug
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo with antipsychotic drug
Number of subjects: 46
Study: 12010380

Group type: EXPERIMENTAL
Intervention: Mouth-dispersible aspirin 900 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 9447289

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) 15 mg once daily (group S)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Methimazole (MMI) 10 mg 3 times daily (group C)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups (C and S)
Number of subjects: 112
Study: 8170855

Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Griseofulvin plus erythromycin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Griseofulvin plus prednisone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Griseofulvin, erythromycin, and prednisone
Number of subjects: 30
Study: 3063268

Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg/d
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Probucol 1 g/d
Number of subjects: 58
Study: 30143475

Group type: EXPERIMENTAL
Intervention: Fixed exercise regimen
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fixed-interactive exercise regimen
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 26787644

Group type: EXPERIMENTAL
Intervention: Stepwise oral misoprostol (50µg followed by two doses of 100µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal misoprostol (three doses of 25µg inserted at intervals of 4h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (oral and vaginal misoprostol)
Number of subjects: 0
Study: 24584583

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie-Ketogenic (VLCK) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Low-Calorie (LC) diet
Number of subjects: 0
Study: 22773672

Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Reverse chin cup
Number of subjects: 42
Study: 20353551

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (LPA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: FM education control (FME)
Number of subjects: 84
Study: 18769081

Group type: EXPERIMENTAL
Intervention: ANP removed after 2 hours (Group II)
Number of subjects: 74

Group type: COMPARATOR
Intervention: ANP removed after 24 to 48 hours (Group I)
Number of subjects: 74
Study: 15715624

Group type: EXPERIMENTAL
Intervention: Remifentanil (7.5 microg kg(‐1). h(‐1))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil (30 microg kg(‐1). h(‐1))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All remifentanil groups
Number of subjects: 45
Study: 15003430

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75-225 mg/day)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318